MedTrace Logo

International ALLIANCE Study of Therapies to Prevent Progression of COVID-19

NCT04395768 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2020-09-11

No results posted yet for this study

Summary

COVID-19 is a global pandemic. So far encouraging results have been shown in different parts of the world with the utilisation of hydroxycloroquine, zinc, and azithromycin, and early studies into some of these, plus some with Vitamin C, have also proven beneficial. Vitamin D levels have also been shown to be an important indicator to the severity of symptoms in COVID-19 patients.

Conditions

  • COVID19

Interventions

DIETARY_SUPPLEMENT

Vitamin C

In addition to the active comparator, which is a combination of 2 drugs and 3 dietary supplements, the experimental treatment arm will also receive Vitamin C (intravenous or oral)

DRUG

Hydroxychloroquine

Active comparator group will receive: a combination of 2 drugs and 3 dietary supplements

DRUG

Azithromycin

Active comparator group will receive: a combination of 2 drugs and 3 dietary supplements

DIETARY_SUPPLEMENT

Zinc Citrate

Active comparator group will receive: a combination of 2 drugs and 3 dietary supplements

DIETARY_SUPPLEMENT

Vitamin D3

Active comparator group will receive: a combination of 2 drugs and 3 dietary supplements

DIETARY_SUPPLEMENT

Vitamin B12

Active comparator group will receive: a combination of 2 drugs and 3 dietary supplements

Sponsors & Collaborators

  • National Institute of Integrative Medicine, Australia

    lead OTHER

Principal Investigators

  • Karin Ried, PhD · National Institute of Integrative Medicine, Australia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-09
Primary Completion
2021-09-30
Completion
2021-12-31

Countries

  • Australia

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04395768 on ClinicalTrials.gov